More than one injection of Elonva within one treatment cycle or too high a dose of Elonva and/or (rec)FSH may increase the risk of OHSS. After administration of Elonva, no additional FSH-containing product should be administered prior to stimulation day 8, as this may also increase the risk of OHSS. (See Ovarian Hyperstimulation Syndrome (OHSS) under Precautions.)
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
